ClinicalTrials.gg
CompletedNCT00455923Updated Feb 5, 2018Results posted

SERETIDE Vs FLIXOTIDE In Mild Persistent Asthma (GINAII)

A Phase 4 interventional study of Seretide and Flixotide in Asthma, sponsored by GlaxoSmithKline. Completed at 1 site in Sweden. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-02-05.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 11 months after the study started (first participant enrolled May 2005, registered Apr 2007).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.

Enrollment
73rd of 146
100 · median 100
Started
2005
with 8 others
Phase 4
52 of 147
1 open now
Registered
36th of 147
by date
Lead sponsor
69 of 147
GlaxoSmithKline

Among the 147 studies testing fluticasone in Asthma, this one is the 73rd largest by enrollment of the 146 interventional ones that give a count, is one of 9 that started in 2005, is one of 52 in phase 4, and was the 36th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies testing fluticasone in Asthma, or all of them as a file.
02

Study summary

An 18 months randomised double-blind study with two parallel arms with start dose of inhaled SERETIDE 50/100mcg BD or FLIXOTIDE 100mcg BD, Phase I is 6 months where the patient will be up-titrated until well controlled is achieved, After 6 months the treatment continues without changes during 9 months = PhaseII. The aim is to investigate and evaluate the assumption that the combination therapy with SERETIDE controls mild persistent asthma better than inhaled corticosteroids(FLIXOTIDE) alone.

03

Conditions studied

  • Asthma

Keywords

  • asthma
  • exacerbation
  • persistent
  • bronchial hyperresponsiveness
  • mild
  • GINAII
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing to give .
  • Males or females aged 18-70.
  • Able to understand and complete dairy cards.
  • Mild persistent asthma according to GINA. In addition, at randomisation subjects were required to have: 1. Day time symptoms more than once a week but not every day. 2. Night-time symptoms not more than once a week. 3. >80% predicted 4. PC20 \<8mg/mL

Exclusion criteria

Exclusion Criteria:

  • Change to regular asthma medication in 4-weeks prior to visit 1.
  • Use of oral, depot or parenteral within 8 weeks of visit 1.
  • Lower respiratory tract within 4 weeks of Visit 1
  • Received study drug within 4 weeks of visit
  • Smoking history of >10 pack years of more.
  • Serious uncontrolled disease.
  • Medical conditions or medications known to affect the assessments or endpoints.
  • Evidence of alcohol or drug abuse.
  • Known pregnancy or planned pregnancy.
  • Known or suspected to inhaled corticosteroids, beta-agonists or lactose.
  • Previous enrollment in the study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Seretide

    Eligible participants received a starting dose of 50/100 mcg Seretide (combination of Sal/FP) via Diskus inhaler, twice daily. During the first 6 months, when the asthma was unstable/uncontrolled, dose was increased in a stepwise fashion to 50/250 mcg and 50/500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months.

    Drug: Seretide

  • Experimental
    Flixotide

    Eligible participants received a starting dose of 100 mcg Flixotide (FP only) via Diskus inhaler, twice daily. During the first 6 months, when the asthma was unstable/uncontrolled, dose was increased in a stepwise fashion to 250 mcg and 500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months.

    Drug: Flixotide

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants in Each Arm With a Need for an Increase in Study Medication

    During the first 6 months, when the asthma was unstable/uncontrolled, dose of Seretide (Sal/FP) was increased from 50/100 mcg in a stepwise fashion to 50/250 mcg and 50/500 mcg (if still unstable). Also, dose of Flixotide (FP only), was increased from 100 mcg to 250 mcg and 500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months. Number of participants in each arm with a need for an increase in study medication are presented.

    Time frame: Up to 18 months

Secondary outcomes

  1. Absolute Bronchial Hyper-responsiveness up to 18 Months

    Data for this outcome measure was not collected.

    Time frame: Up to 18 months

  2. Change in Bronchial Hyper-responsiveness From Baseline to 18 Months

    Data for this outcome measure was not collected.

    Time frame: Baseline (Day 0) to 18 months

  3. Number of Symptom-free Days and Nights Without Use of Rescue Medication

    The rescue medications used for exacerbations included Ventoline Diskus® 200 mcg/dose inhalations as required and oral Prednisolone 25 mg per day for five days, and when necessary, ten days. Data for this outcome measure was not collected.

    Time frame: Up to 18 months

  4. Number of Exacerbations: in Total and by Degree of Severity

    Severe exacerbation: needed hospitalization/emergency unit visit. Moderate exacerbation: Needed oral cortico-steroid or adding inhaled Flixotide to maintenance study medicine; decrease in morning or evening peak expiratory flow (PEF) \> 30% during ≥ 2 following days from Baseline (Day 0). Mild exacerbation: any night symptoms ≥ 3 consecutive, or night symptoms ≥ 2 consecutive nights in case symptoms have been scored ≥ 2 during at least one night, Day symptoms scored ≥ 2 during ≥ 4 following days, or Day symptoms scored ≥ 3 during ≥ 3 following days, or Day symptoms scored ≥ 4 during ≥ 2 following days, or rescue medication use ≥ 2 occasions per day for ≥ 4 following days, or rescue medication use ≥ 3 occasions per day for ≥ 3 following days, or rescue medication use ≥ 4 occasions per day for ≥ 2 following days, or decrease in morning/evening PEF \>20% during ≥ 2 following days from Baseline (Day 0). Number of total exacerbations and severe, moderate and mild exacerbations are presented.

    Time frame: Up to 18 months

  5. Time to Increase of Study Medication

    Data for this outcome measure was not collected.

    Time frame: Up to 6 months

07

Results

Posted Jan 4, 2018

Participant flow

This study was conducted at a single center with two sites in Sweden from May 2005 to July 2007. Seretide Diskus®, Flixotide® and Ventoline Diskus® are the registered products of GlaxoSmithKline.

Participant flow — Overall Study
MilestoneSeretideFlixotide
Started5050
Completed4747
Not completed33
Withdrew: Pregnancy02
Withdrew: Other31

Outcome measures

PrimaryNumber of Participants in Each Arm With a Need for an Increase in Study Medication

During the first 6 months, when the asthma was unstable/uncontrolled, dose of Seretide (Sal/FP) was increased from 50/100 mcg in a stepwise fashion to 50/250 mcg and 50/500 mcg (if still unstable). Also, dose of Flixotide (FP only), was increased from 100 mcg to 250 mcg and 500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months. Number of participants in each arm with a need for an increase in study medication are presented.

Time frame:
Up to 18 months
Reported as:
Count of participants · Participants
Number of Participants in Each Arm With a Need for an Increase in Study Medication
ParticipantsSeretideFlixotide
Number of Participants in Each Arm With a Need for an Increase in Study Medication2929
SecondaryAbsolute Bronchial Hyper-responsiveness up to 18 Months

Data for this outcome measure was not collected.

Time frame:
Up to 18 months

No measurements were reported for this outcome.

SecondaryChange in Bronchial Hyper-responsiveness From Baseline to 18 Months

Data for this outcome measure was not collected.

Time frame:
Baseline (Day 0) to 18 months

No measurements were reported for this outcome.

SecondaryNumber of Symptom-free Days and Nights Without Use of Rescue Medication

The rescue medications used for exacerbations included Ventoline Diskus® 200 mcg/dose inhalations as required and oral Prednisolone 25 mg per day for five days, and when necessary, ten days. Data for this outcome measure was not collected.

Time frame:
Up to 18 months

No measurements were reported for this outcome.

SecondaryNumber of Exacerbations: in Total and by Degree of Severity

Severe exacerbation: needed hospitalization/emergency unit visit. Moderate exacerbation: Needed oral cortico-steroid or adding inhaled Flixotide to maintenance study medicine; decrease in morning or evening peak expiratory flow (PEF) \> 30% during ≥ 2 following days from Baseline (Day 0). Mild exacerbation: any night symptoms ≥ 3 consecutive, or night symptoms ≥ 2 consecutive nights in case symptoms have been scored ≥ 2 during at least one night, Day symptoms scored ≥ 2 during ≥ 4 following days, or Day symptoms scored ≥ 3 during ≥ 3 following days, or Day symptoms scored ≥ 4 during ≥ 2 following days, or rescue medication use ≥ 2 occasions per day for ≥ 4 following days, or rescue medication use ≥ 3 occasions per day for ≥ 3 following days, or rescue medication use ≥ 4 occasions per day for ≥ 2 following days, or decrease in morning/evening PEF \>20% during ≥ 2 following days from Baseline (Day 0). Number of total exacerbations and severe, moderate and mild exacerbations are presented.

Time frame:
Up to 18 months
Reported as:
Number · Exacerbations
Number of Exacerbations: in Total and by Degree of Severity
ExacerbationsSeretideFlixotide
Total exacerbations4274
Severe exacerbations01
Moderate exacerbations1221
Mild exacerbations3052
SecondaryTime to Increase of Study Medication

Data for this outcome measure was not collected.

Time frame:
Up to 6 months

No measurements were reported for this outcome.

Adverse events

Collected over Up to 18 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Seretide0/50 (0%)3/50 (6%)48/50 (96%)
Flixotide0/50 (0%)0/50 (0%)47/50 (94%)
Most frequent serious events
Most frequent serious events
EventSeretideFlixotide
Colon diverticulitisGastrointestinal disorders1/500/50
Migraine/headacheNervous system disorders1/500/50
CholecystitisHepatobiliary disorders1/500/50
Most frequent other events
Most frequent other events
EventSeretideFlixotide
Common coldInfections and infestations45/5039/50
Upper airway infectionsInfections and infestations14/5015/50
GastroenteritisInfections and infestations9/508/50
HeadacheNervous system disorders8/507/50
PharyngitisInfections and infestations7/504/50
BronchitisInfections and infestations4/505/50
Upper back painMusculoskeletal and connective tissue disorders4/505/50
Chest painGeneral disorders1/505/50
Mouth candidaInfections and infestations2/504/50
SinusitisInfections and infestations3/501/50

Baseline characteristics

Age, Customized
Age, Customized(Participants)SeretideFlixotideTotal
>=18 to 70 years5050100
Sex: Female, Male
Sex: Female, Male(Participants)SeretideFlixotideTotal
Female323163
Male181937
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SeretideFlixotideTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White5050100
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • GSK Investigational Site
    Luleå, SE-971 89, Sweden
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2005 to primary completion in Jul 2007, 26 months.

Results were first posted in Jan 2018, 10 years 5 months after primary completion.

Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 26 months is above that.

Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2007
First posted
Apr 4, 2007
StartActual
May 3, 2005
Primary completionActual
Jul 31, 2007
CompletionActual
Jul 31, 2007
Results first posted
Jan 4, 2018
Last update
Feb 5, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00455923
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 4, 2007
Start date
May 3, 2005
Primary completion
Jul 31, 2007
Completion
Jul 31, 2007
Results posted
Jan 4, 2018
Last update
Feb 5, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone

Start the discussion